Exploring yeast glucans for vaccine enhancement: Sustainable strategies for overcoming adjuvant challenges in a SARS-CoV-2 model.

Autor: Azevedo-Silva J; CBQF-Centro de Biotecnologia e Química Fina-Laboratório Associado, Escola Superior de Biotecnologia, Universidade Católica Portuguesa, 4169-005, Porto, Portugal., Amorim M; CBQF-Centro de Biotecnologia e Química Fina-Laboratório Associado, Escola Superior de Biotecnologia, Universidade Católica Portuguesa, 4169-005, Porto, Portugal., Tavares-Valente D; CBQF-Centro de Biotecnologia e Química Fina-Laboratório Associado, Escola Superior de Biotecnologia, Universidade Católica Portuguesa, 4169-005, Porto, Portugal., Sousa P; CBQF-Centro de Biotecnologia e Química Fina-Laboratório Associado, Escola Superior de Biotecnologia, Universidade Católica Portuguesa, 4169-005, Porto, Portugal., Mohamath R; Access to Advanced Health Institute, Formerly Infectious Disease Research Institute, Seattle, WA, USA., Voigt EA; Access to Advanced Health Institute, Formerly Infectious Disease Research Institute, Seattle, WA, USA., Guderian JA; Access to Advanced Health Institute, Formerly Infectious Disease Research Institute, Seattle, WA, USA., Kinsey R; Access to Advanced Health Institute, Formerly Infectious Disease Research Institute, Seattle, WA, USA., Viana S; University of Coimbra, Faculty of Medicine, Institute of Pharmacology & Experimental Therapeutics & Coimbra Institute for Clinical and Biomedical Research (iCBR), 3000-548, Coimbra, Portugal; University of Coimbra, Center for Innovative Biomedicine and Biotechnology (CIBB), 3004-504, Coimbra, Portugal; Clinical Academic Center of Coimbra (CACC), 3004-504, Coimbra, Portugal; Pharmacy, Coimbra Health School, Polytechnic Institute of Coimbra, Rua 5 de Outubro-SM Bispo, Apartado 7006 3046-854, Coimbra, Portugal., Reis F; University of Coimbra, Faculty of Medicine, Institute of Pharmacology & Experimental Therapeutics & Coimbra Institute for Clinical and Biomedical Research (iCBR), 3000-548, Coimbra, Portugal; University of Coimbra, Center for Innovative Biomedicine and Biotechnology (CIBB), 3004-504, Coimbra, Portugal; Clinical Academic Center of Coimbra (CACC), 3004-504, Coimbra, Portugal., Pintado ME; CBQF-Centro de Biotecnologia e Química Fina-Laboratório Associado, Escola Superior de Biotecnologia, Universidade Católica Portuguesa, 4169-005, Porto, Portugal., Paddon CJ; Amyris, Inc., Emeryville, CA, USA., Fox CB; Access to Advanced Health Institute, Formerly Infectious Disease Research Institute, Seattle, WA, USA., Fernandes JC; CBQF-Centro de Biotecnologia e Química Fina-Laboratório Associado, Escola Superior de Biotecnologia, Universidade Católica Portuguesa, 4169-005, Porto, Portugal. Electronic address: jcfernandes@ucp.pt.

Publikováno v: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V [Eur J Pharm Biopharm] 2024 Oct 24, pp. 114538. Date of Electronic Publication: 2024 Oct 24.

Screening of Oligomeric (Meth)acrylate Vaccine Adjuvants Synthesized via Catalytic Chain Transfer Polymerization.

Autor: Hege CS; Centre for Additive Manufacturing, Department of Chemical and Environmental Engineering, University of Nottingham, Nottingham NG7 2RD, UK., Stimpson A; Centre for Additive Manufacturing, Department of Chemical and Environmental Engineering, University of Nottingham, Nottingham NG7 2RD, UK., Sefton J; Centre for Additive Manufacturing, Department of Chemical and Environmental Engineering, University of Nottingham, Nottingham NG7 2RD, UK., Summers J; School of Chemistry, University of Nottingham, Nottingham NG7 2RD, UK., Henke H; Centre for Additive Manufacturing, Department of Chemical and Environmental Engineering, University of Nottingham, Nottingham NG7 2RD, UK., Dundas AA; Centre for Additive Manufacturing, Department of Chemical and Environmental Engineering, University of Nottingham, Nottingham NG7 2RD, UK., Phan T; Access to Advanced Health Institute, Formerly Infectious Disease Research Institute, Seattle, WA 98102, USA., Kinsey R; Access to Advanced Health Institute, Formerly Infectious Disease Research Institute, Seattle, WA 98102, USA., Guderian JA; Access to Advanced Health Institute, Formerly Infectious Disease Research Institute, Seattle, WA 98102, USA., Sivananthan SJ; Access to Advanced Health Institute, Formerly Infectious Disease Research Institute, Seattle, WA 98102, USA., Mohamath R; Access to Advanced Health Institute, Formerly Infectious Disease Research Institute, Seattle, WA 98102, USA., Lykins WR; Access to Advanced Health Institute, Formerly Infectious Disease Research Institute, Seattle, WA 98102, USA., Ramer-Denisoff G; Access to Advanced Health Institute, Formerly Infectious Disease Research Institute, Seattle, WA 98102, USA., Lin S; Access to Advanced Health Institute, Formerly Infectious Disease Research Institute, Seattle, WA 98102, USA., Fox CB; Access to Advanced Health Institute, Formerly Infectious Disease Research Institute, Seattle, WA 98102, USA.; Department of Global Health, University of Washington, Seattle, WA 98104, USA., Irvine DJ; Centre for Additive Manufacturing, Department of Chemical and Environmental Engineering, University of Nottingham, Nottingham NG7 2RD, UK.

Publikováno v: Polymers [Polymers (Basel)] 2023 Sep 20; Vol. 15 (18). Date of Electronic Publication: 2023 Sep 20.

Semi-synthetic terpenoids with differential adjuvant properties as sustainable replacements for shark squalene in vaccine emulsions.

Autor: Fisher KJ; Amyris, Inc., Emeryville, CA, USA., Kinsey R; Access to Advanced Health Institute, formerly Infectious Disease Research Institute, Seattle, WA, USA., Mohamath R; Access to Advanced Health Institute, formerly Infectious Disease Research Institute, Seattle, WA, USA., Phan T; Infectious Disease Research Institute, Seattle, WA, USA.; Neoleukin, Seattle, WA, USA., Liang H; Infectious Disease Research Institute, Seattle, WA, USA.; Bristol-Myers Squibb, Seattle, WA, USA., Orr MT; Infectious Disease Research Institute, Seattle, WA, USA.; Bristol-Myers Squibb, Seattle, WA, USA., Lykins WR; Access to Advanced Health Institute, formerly Infectious Disease Research Institute, Seattle, WA, USA., Guderian JA; Access to Advanced Health Institute, formerly Infectious Disease Research Institute, Seattle, WA, USA., Bakken J; Access to Advanced Health Institute, formerly Infectious Disease Research Institute, Seattle, WA, USA., Argilla D; Access to Advanced Health Institute, formerly Infectious Disease Research Institute, Seattle, WA, USA., Ramer-Denisoff G; Access to Advanced Health Institute, formerly Infectious Disease Research Institute, Seattle, WA, USA., Larson E; Access to Advanced Health Institute, formerly Infectious Disease Research Institute, Seattle, WA, USA., Qi Y; Access to Advanced Health Institute, formerly Infectious Disease Research Institute, Seattle, WA, USA., Sivananthan S; Access to Advanced Health Institute, formerly Infectious Disease Research Institute, Seattle, WA, USA., Smolyar K; Infectious Disease Research Institute, Seattle, WA, USA., Carter D; Infectious Disease Research Institute, Seattle, WA, USA.; HDT Bio Corp., Seattle, WA, USA.; PAI Life Sciences Inc., Seattle, WA, USA., Paddon CJ; Amyris, Inc., Emeryville, CA, USA. paddon@amyris.com., Fox CB; Access to Advanced Health Institute, formerly Infectious Disease Research Institute, Seattle, WA, USA. christopher.fox@aahi.org.; Department of Global Health, University of Washington, Seattle, WA, USA. christopher.fox@aahi.org.

Publikováno v: NPJ vaccines [NPJ Vaccines] 2023 Feb 16; Vol. 8 (1), pp. 14. Date of Electronic Publication: 2023 Feb 16.

A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability.

Autor: Voigt EA; RNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA. emily.voigt@aahi.org., Gerhardt A; Product Development, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA., Hanson D; RNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA., Jennewein MF; RNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA., Battisti P; RNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA., Reed S; Product Development, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA., Singh J; RNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA., Mohamath R; Formulation Sciences, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA., Bakken J; RNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA., Beaver S; RNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA., Press C; Product Development, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA., Soon-Shiong P; ImmunityBio, Inc, Culver City, CA, 90232, USA., Paddon CJ; Amyris, Inc, Emeryville, CA, 94608, USA., Fox CB; Formulation Sciences, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA.; Department of Global Health, University of Washington, Seattle, WA, 98195, USA., Casper C; RNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA.; Product Development, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA.; Formulation Sciences, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA.; Department of Global Health, University of Washington, Seattle, WA, 98195, USA.; Department of Medicine, University of Washington, Seattle, WA, 98195, USA.; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, USA.

Publikováno v: NPJ vaccines [NPJ Vaccines] 2022 Nov 02; Vol. 7 (1), pp. 136. Date of Electronic Publication: 2022 Nov 02.

EXTRACTO ETÉREO EN SEMILLAS DE ZAPALLO (Cucurbita moschata Duchesne) EN TRES GENERACIONES DE ENDOCRÍA.

Autor: Valdés Restrepo, Magda Piedad¹ magda.valdes@unad.edu.co, Ordoñez Narváez, Ginna Alejandra² ginna.ordonez@unad.edu.co, Ortiz Grisales, Sanín³ sortizg@unal.edu.co

Publikováno v: Revista de Investigación Agraria y Ambiental. jul-dic2024, Vol. 15 Issue 2, p113-128. 16p.